Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Geron

DB:GON
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GON
DB
$210M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Geron has significant price volatility in the past 3 months.
GON Share Price and Events
7 Day Returns
-4.7%
DB:GON
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-47.3%
DB:GON
-7.4%
DE Biotechs
-14.2%
DE Market
GON Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Geron (GON) -4.7% 5.5% -20.2% -47.3% -57% -75.3%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • GON underperformed the Biotechs industry which returned -7.4% over the past year.
  • GON underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
GON
Industry
5yr Volatility vs Market

GON Value

 Is Geron undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Geron to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Geron.

DB:GON Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GON
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (1.21%))
1.039
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.039 * 5.44%)
5.26%

Discounted Cash Flow Calculation for DB:GON using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Geron is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:GON DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.26%)
2020 -88.03 Analyst x1 -83.63
2021 -78.38 Analyst x1 -70.74
2022 -47.55 Analyst x1 -40.77
2023 7.69 Analyst x1 6.26
2024 137.02 Analyst x1 106.03
2025 236.31 Est @ 72.46% 173.72
2026 355.88 Est @ 50.6% 248.55
2027 481.53 Est @ 35.3% 319.48
2028 599.97 Est @ 24.6% 378.17
2029 702.56 Est @ 17.1% 420.70
Present value of next 10 years cash flows $1,457.00
DB:GON DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $702.56 × (1 + -0.39%) ÷ (5.26% – -0.39%)
$12,381.95
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,381.95 ÷ (1 + 5.26%)10
$7,414.37
DB:GON Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,457.00 + $7,414.37
$8,871.37
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $8,871.37 / 200.34
$44.28
DB:GON Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GON represents 0.88445x of NasdaqGS:GERN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88445x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 44.28 x 0.88445
€39.16
Value per share (EUR) From above. €39.16
Current discount Discount to share price of €0.96
= -1 x (€0.96 - €39.16) / €39.16
97.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Geron is available for.
Intrinsic value
>50%
Share price is €0.96 vs Future cash flow value of €39.16
Current Discount Checks
For Geron to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Geron's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Geron's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Geron's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Geron's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GON PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.36
NasdaqGS:GERN Share Price ** NasdaqGS (2020-04-08) in USD $1.08
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Geron.

DB:GON PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:GERN Share Price ÷ EPS (both in USD)

= 1.08 ÷ -0.36

-3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Geron is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Geron is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Geron's expected growth come at a high price?
Raw Data
DB:GON PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
13.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Geron, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Geron's assets?
Raw Data
DB:GON PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.68
NasdaqGS:GERN Share Price * NasdaqGS (2020-04-08) in USD $1.08
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:GON PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:GERN Share Price ÷ Book Value per Share (both in USD)

= 1.08 ÷ 0.68

1.6x

* Primary Listing of Geron.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Geron is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Geron's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Geron has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GON Future Performance

 How is Geron expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Geron expected to grow at an attractive rate?
  • Geron's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Geron's earnings growth is positive but not above the Germany market average.
  • Geron's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GON Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GON Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 13.4%
DB:GON Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 63.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GON Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GON Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 193 148 2 2
2023-12-31 64 3 -71 2
2022-12-31 18 -22 -80 2
2021-12-31 0 -80 -101 4
2020-12-31 0 -98 -95 5
2020-04-08
DB:GON Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -44 -69
2019-09-30 1 -36 -47
2019-06-30 1 -31 -37
2019-03-31 1 -26 -30
2018-12-31 1 -21 -27
2018-09-30 1 -22 -27
2018-06-30 1 -21 -28
2018-03-31 1 -21 -28
2017-12-31 1 -21 -28
2017-09-30 1 -17 -29
2017-06-30 6 -19 -26
2017-03-31 6 -20 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Geron's earnings are expected to grow by 13.4% yearly, however this is not considered high growth (20% yearly).
  • Geron's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GON Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Geron Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GON Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.02 0.74 -0.71 2.00
2023-12-31 -0.32 0.07 -0.70 2.00
2022-12-31 -0.37 -0.24 -0.49 2.00
2021-12-31 -0.49 -0.37 -0.78 4.00
2020-12-31 -0.47 -0.37 -0.74 4.00
2020-04-08
DB:GON Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.36
2019-09-30 -0.25
2019-06-30 -0.20
2019-03-31 -0.16
2018-12-31 -0.15
2018-09-30 -0.16
2018-06-30 -0.17
2018-03-31 -0.17
2017-12-31 -0.18
2017-09-30 -0.18
2017-06-30 -0.16
2017-03-31 -0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Geron will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Geron's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Geron has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GON Past Performance

  How has Geron performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Geron's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Geron does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Geron's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Geron's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Geron's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Geron Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GON Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.46 -68.55 20.89 12.81
2019-09-30 0.66 -46.78 20.52 9.76
2019-06-30 0.70 -37.20 19.79 6.89
2019-03-31 0.81 -29.89 18.84 4.34
2018-12-31 1.07 -27.02 18.71 3.08
2018-09-30 0.88 -27.15 19.28 2.62
2018-06-30 0.88 -28.45 19.79 2.46
2018-03-31 0.85 -27.92 19.95 2.36
2017-12-31 1.07 -27.92 19.29 2.60
2017-09-30 0.97 -28.97 18.59 2.69
2017-06-30 5.91 -25.65 18.48 2.84
2017-03-31 5.95 -27.88 18.63 3.08
2016-12-31 6.16 -29.54 18.76 3.35
2016-09-30 6.29 -29.52 18.89 3.96
2016-06-30 36.54 1.24 18.56 4.69
2016-03-31 36.58 0.52 17.99 6.14
2015-12-31 36.37 0.05 17.79 8.26
2015-09-30 36.33 -0.43 17.75 9.99
2015-06-30 1.13 -37.17 17.49 11.17
2015-03-31 1.22 -36.55 17.36 11.71
2014-12-31 1.15 -35.67 16.76 11.81
2014-09-30 1.20 -36.00 15.90 11.63
2014-06-30 1.22 -34.71 15.29 11.63
2014-03-31 0.99 -34.92 14.87 12.08
2013-12-31 1.28 -38.38 15.62 14.02
2013-09-30 1.75 -44.96 16.31 17.58
2013-06-30 2.20 -52.66 17.68 21.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Geron has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Geron has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Geron improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Geron's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Geron has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GON Health

 How is Geron's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Geron's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Geron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Geron's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Geron's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -3.1887286801634E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Geron Company Filings, last reported 3 months ago.

DB:GON Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 135.16 0.00 139.33
2019-09-30 152.39 0.00 138.61
2019-06-30 157.04 0.00 152.49
2019-03-31 169.41 0.00 151.98
2018-12-31 177.73 0.00 163.29
2018-09-30 183.47 0.00 166.35
2018-06-30 178.36 0.00 160.93
2018-03-31 101.13 0.00 89.78
2017-12-31 103.80 0.00 94.69
2017-09-30 108.27 0.00 96.90
2017-06-30 113.01 0.00 94.85
2017-03-31 117.25 0.00 99.29
2016-12-31 122.38 0.00 114.85
2016-09-30 128.91 0.00 108.54
2016-06-30 130.31 0.00 110.60
2016-03-31 136.49 0.00 109.65
2015-12-31 142.13 0.00 113.77
2015-09-30 147.89 0.00 119.68
2015-06-30 118.36 0.00 138.01
2015-03-31 125.18 0.00 145.84
2014-12-31 130.71 0.00 151.44
2014-09-30 137.18 0.00 126.40
2014-06-30 144.58 0.00 140.34
2014-03-31 150.89 0.00 145.19
2013-12-31 59.76 0.00 65.22
2013-09-30 61.88 0.00 66.21
2013-06-30 68.41 0.00 70.80
  • Geron's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Geron's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Geron has sufficient cash runway for more than 3 years based on current free cash flow.
  • Geron has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 13.2% each year.
X
Financial health checks
We assess Geron's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Geron has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GON Dividends

 What is Geron's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Geron dividends.
If you bought €2,000 of Geron shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Geron's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Geron's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GON Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GON Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Geron has not reported any payouts.
  • Unable to verify if Geron's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Geron's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Geron has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Geron's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Geron afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Geron has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GON Management

 What is the CEO of Geron's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chip Scarlett
COMPENSATION $2,772,509
AGE 68
TENURE AS CEO 8.6 years
CEO Bio

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman of the Board at Geron Corporation since December 27, 2018. Dr. Scarlett served as Chief Executive Officer and President of Onyx Therapeutics, Inc. since February 2009. He Co-Founded Ipsen Biopharmaceuticals, Inc. (Formerly Tercica Inc) in 2002 and served as its Chief Executive Officer from February 2002 to October 2008. Dr. Scarlett served as Chief Executive Officer and President of Proteolix, Inc. from February 2009 to November 2009. Dr. Scarlett has nearly 30 years of experience in drug development and commercialization. He served as President of Ipsen Biopharmaceuticals, Inc., from February 2002 to February 27, 2008. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. Prior to Tercica, Dr. Scarlett founded Sensus Drug Development Corporation. He Co-founded Covance Biotechnology Services, Inc., in 1995. From 1991 to 1993, he headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk A/S. From 1985 to 1990, Dr. Scarlett served as Vice President of Clinical Affairs and headed the clinical development group of Greenwich Pharmaceuticals, Inc. From 1982 to 1985, he served as Associate Director and subsequently, as Director, of Medical Research and Services of McNeil Pharmaceuticals, a wholly-owned subsidiary of Johnson & Johnson, Inc. He has been an Independent Director of Chiasma, Inc. since February 24, 2015. He serves as Director of Onyx Therapeutics, Inc. He has been a Director of Geron Corporation since September 2011 and CytomX Therapeutics, Inc. since June 13, 2016. Dr. Scarlett served as Director of Ipsen Biopharmaceuticals, Inc. from February 2002 to October 2008. He served as a member of board of directors of Covance Biotechnology Services, Inc. since 2000 and Proteolix, Inc. from February 2009 to November 2009. He received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. Dr. Scarlett trained in Internal Medicine at the Hospital at the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center.

CEO Compensation
  • Chip's compensation has increased whilst company is loss making.
  • Chip's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Geron management team in years:

4.3
Average Tenure
55
Average Age
  • The tenure for the Geron management team is about average.
Management Team

Chip Scarlett

TITLE
CEO, President & Chairman of the Board
COMPENSATION
$3M
AGE
68
TENURE
8.6 yrs

Olivia Bloom

TITLE
Executive VP of Finance
COMPENSATION
$1M
AGE
50
TENURE
7.3 yrs

Andrew Grethlein

TITLE
Executive VP & COO
COMPENSATION
$1M
AGE
55
TENURE
1.3 yrs

Stephen Rosenfield

TITLE
Executive VP
COMPENSATION
$1M
AGE
69
TENURE
8.3 yrs

Melissa A. Behrs

TITLE
Executive VP & Chief Business Officer
COMPENSATION
$1M
AGE
55
TENURE
13.3 yrs

Suzanne Messere

TITLE
Head of Investor Relations & Corporate Communications

Shannon Odam

TITLE
Vice President of Human Resources
TENURE
0.8 yrs

Aleksandra Rizo

TITLE
Executive VP & Chief Medical Officer
AGE
44
TENURE
1.3 yrs

Anil Kapur

TITLE
Chief Commercial Officer & Executive VP of Corporate Strategy
AGE
49
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Geron board of directors in years:

1.3
Average Tenure
67
Average Age
  • The average tenure for the Geron board of directors is less than 3 years, this suggests a new board.
Board of Directors

Karin Eastham

TITLE
Lead Independent Director
COMPENSATION
$239K
AGE
70
TENURE
1.3 yrs

Chip Scarlett

TITLE
CEO, President & Chairman of the Board
COMPENSATION
$3M
AGE
68
TENURE
1.3 yrs

Bob Spiegel

TITLE
Independent Director
COMPENSATION
$222K
AGE
70
TENURE
9.9 yrs

Susan Molineaux

TITLE
Independent Director
COMPENSATION
$217K
AGE
65
TENURE
7.6 yrs

V. Lawlis

TITLE
Independent Director
COMPENSATION
$227K
AGE
67
TENURE
8.1 yrs

Dawn Bir

TITLE
Independent Director
AGE
48
TENURE
1.1 yrs

Liz O'Farrell

TITLE
Independent Director
AGE
54
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Geron individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Jan 20 Buy Elizabeth O'Farrell Individual 10. Jan 20 10. Jan 20 3,000 €1.21 €3,624
X
Management checks
We assess Geron's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Geron has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GON News

Simply Wall St News

GON Company Info

Description

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

Details
Name: Geron Corporation
GON
Exchange: DB
Founded: 1990
$193,448,940
200,344,809
Website: http://www.geron.com
Address: Geron Corporation
149 Commonwealth Drive,
Suite 2070,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS GERN Common Stock Nasdaq Global Select US USD 31. Jul 1996
DB GON Common Stock Deutsche Boerse AG DE EUR 31. Jul 1996
LSE 0IV3 Common Stock London Stock Exchange GB USD 31. Jul 1996
BRSE GON Common Stock Berne Stock Exchange CH CHF 31. Jul 1996
Number of employees
Current staff
Staff numbers
46
Geron employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:03
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.